Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04455932
Registration number
NCT04455932
Ethics application status
Date submitted
27/06/2020
Date registered
2/07/2020
Date last updated
8/09/2021
Titles & IDs
Public title
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
Query!
Scientific title
HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation
Query!
Secondary ID [1]
0
0
2019/PID15472
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hepatocellular Carcinoma
0
0
Query!
HCC
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Liver
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Diagnosis / Prognosis - Abbreviated non-contrast MRI of the liver
Diagnosis / Prognosis - Ultrasound surveillance
Diagnosis / Prognosis - Multiphase contrast-enhanced liver MRI
Experimental: HCC surveillance with US and aNC-MRI -
Diagnosis / Prognosis: Abbreviated non-contrast MRI of the liver
every 6 months
Diagnosis / Prognosis: Ultrasound surveillance
every 6 months
Diagnosis / Prognosis: Multiphase contrast-enhanced liver MRI
screening
Query!
Intervention code [1]
0
0
Diagnosis / Prognosis
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
HCC detection with US surveillance versus aNC-MRI surveillance
Query!
Assessment method [1]
0
0
The detection of hepatic malignancy on the two modalities will be compared
Sensitivity, specificity, PPV and NPV of HCC detection with US surveillance vs aNC-MRI surveillance
Correlation with diagnostic imaging (multiphase CT or MRI) and/or histopathology as a reference standard
For the diagnosis of HCC we will accept
Imaging diagnosis based on the Liver Imaging Reporting and Data System (LI-RADS)
Any pathological proof on biopsy or excision The HCC will then be staged based on the Barcelona clinic liver cancer (BCLC) staging system
For the diagnosis of non-HCC hepatic malignancy we will accept
Imaging diagnosis based on the Liver Imaging Reporting and Data System (LI-RADS)
Any pathological proof on biopsy or excision
Query!
Timepoint [1]
0
0
3 or 5 years
Query!
Eligibility
Key inclusion criteria
Inclusion criteria
- Patients with cirrhosis (all causes of cirrhosis, except obscure causes such as
vascular or congenital fibrosis) AND reduced visualisation of their liver on
ultrasound (vB and vC).
- The criteria of cirrhosis can be obtained with any of the following methods:
1. Histologically by liver biopsy
2. Past signs of decompensated liver disease such as ascites, encephalopathy,
varices or bacterial peritonitis
3. Clinically suspicion of cirrhosis PLUS one of the following:
1. Radiological evidence of morphologic changes of the liver and evidence of
portal hypertension on US, CT or MRI examinations, including the
identification of hepatic surface nodularity, splenomegaly, portal
collaterals, varices and ascites
2. Fibroscan (transient elastography) median liver stiffness >12.5 kPa, the
Fibroscan must be performed by an experienced technician and interpreted by
the hepatologist
3. Platelet count <100 (x10^9/L) with no alternative cause
- Absence of previous history or current suspicion of HCC - Absence of HCC is defined by
liver US, multiphase CT or contrast-enhanced MRI within 6 months prior to surveillance
- Patient is able to comply with scheduled visits, evaluation plans and other study
procedures in the opinion of the investigator
- Patient is willing to provide written informed consent
Query!
Minimum age
20
Years
Query!
Query!
Maximum age
85
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria
- Contraindications to MRI scan (defibrillator, pacemaker, metallic foreign body, severe
claustrophobia etc.)
- Contraindications to gadolinium
- Age above 85 years old or younger than 20 years old
- Pregnancy or breast feeding
- Any other condition which, in the opinion of the Investigator, would make the patient
unsuitable for enrolment for the trial or could interfere with the completion of the
study
Query!
Study design
Purpose of the study
Screening
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
1/01/2022
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/03/2027
Query!
Actual
Query!
Sample size
Target
476
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [2]
0
0
Concord Repatriation General Hospital - Concord
Query!
Recruitment hospital [3]
0
0
Gosford Hospital - Gosford
Query!
Recruitment hospital [4]
0
0
Prince of Wales Hospital - Randwick
Query!
Recruitment hospital [5]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [6]
0
0
Princess Alexandra Hospital - Brisbane
Query!
Recruitment hospital [7]
0
0
St Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment hospital [8]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [9]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [3]
0
0
- Gosford
Query!
Recruitment postcode(s) [4]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [5]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [6]
0
0
- Brisbane
Query!
Recruitment postcode(s) [7]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [8]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [9]
0
0
- Perth
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Auckland
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Concord Repatriation General Hospital
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
All international guidelines recommend 6-monthly ultrasound surveillance for patients at risk
for liver cancer (hepatocellular carcinoma or HCC), such as patients with cirrhosis. The aim
of surveillance is to detect HCC at an early stage when it is still potentially curable.
Currently only 4 out of 10 HCCs are detected at the early stage.
Ultrasound surveillance for HCC has a wide ranging sensitivity, dependent on many factors
such as operator experience, patient body habitus and liver parenchymal heterogeneity due to
chronic liver disease and cirrhosis. In a select group of patients, surveillance ultrasound
can be suboptimal or near non-diagnostic.
Currently no guideline offers an alternative surveillance tool for patients who have
suboptimal surveillance ultrasounds.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04455932
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Jessica Yang, MBBS
Query!
Address
0
0
Concord Repatriation General Hospital
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Jessica Yang, MBBS
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+61297676495
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04455932
Download to PDF